NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE
InnovaDerma PLC
("InnovaDerma" or the "Company")
Acquisition of Remaining Minority Shareholding in Skinny Tan
InnovaDerma (LSE: IDP), a leading digitally focused
Consideration for the Acquisition
The total consideration payable for the Acquisition is AUD$0.96 million. This consists of cash consideration of AUD$0.48 million (
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for 683,152 new Ordinary Shares to be admitted to trading ("Admission"). It is expected that Admission will become effective, and dealings will commence, at 8.00 a.m. on 10 January 2022.
Following Admission, the Company will have in issue 28,057,825 Ordinary Shares, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Blake Hughes, CEO InnovaDerma PLC, commented
"InnovaDerma acquired an initial 80% of the share capital of Skinny Tan from founders Louise and Kate back in 2015, since then the brand has gone from strength to strength and become one of the best-selling self-tanning brands in the
Over the years we have built our ownership to 96% and as we enter into a new phase of profitable growth for InnovaDerma, I'm pleased that we have now acquired the remaining shares in our flagship brand, Skinny Tan. This resolves a legacy situation and further simplifies our Company.
I look forward to continuing to work with Louise to maximise the potential of Skinny Tan as we launch new products and further expand the Skinny Tan business into existing and new geographies."
Further enquiries
InnovaDerma Blake Hughes |
c/o TB Cardew |
finnCap Ltd Geoff Nash/Kate Bannatyne Alice Lane - Corporate Broking |
+44 (0)207 220 0500 |
TB Cardew |
|
Shan Shan Willenbrock/ |
+ 44 (0)7775 848537 |
Olivia Rosser |
+ 44 (0)7552 864250 |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.